iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Suven Pharma says Casper Pharma completes USFDA pre-approval inspection

30 Jul 2022 , 02:55 PM

Casper Pharma is a wholly-owned subsidiary of Suven Pharmaceuticals, Hyderabad, India. The inspection was conducted from 25 July through 29 July 2022. The audit is part of the agencys inspection for three product applications filed and slated to be manufactured at this site. We are glad to have completed the audit successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA which signifies compliance and conformance to applicable cGMP regulations, Venkat Jasti, managing director of Suven Pharmaceuticals said in a statement. In April 2022, the board of Suven Pharma approved acquisition of Hyderabad-based Casper Pharmaceuticals for Rs 155 crore. Casper is engaged in formulations business. Hyderabad-based Suven Pharmaceuticals is a pure-play contract development and manufacturing company (CDMO) player. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. On a consolidated basis, net profit of Suven Pharmaceuticals rose 10.29% to Rs 91.67 crore on 40.40% rise in net sales to Rs 363.85 crore in Q4 March 2022 over Q4 March 2021. Shares of Suven Pharma rose 2.21% to Rs 481.15 on Friday, 29 July 2022. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.